JPMorgan analyst Richard Vosser lowered the firm’s price target on Molecular Partners (MOLN) to $4 from $4.50 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOLN:
- Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
- Promising Developments and Strategic Resource Management Justify Buy Rating for Molecular Partners AG
- Molecular Partners AG Reports H1 2025 Progress
- Molecular Partners’ Promising Pipeline and Strategic Advancements Justify Buy Rating
- Molecular Partners Advances Clinical Programs and Strengthens Financial Position in H1 2025